| Literature DB >> 31571942 |
Zeqiang Zhan1, Xuebin Xu2, Zhen Gu3, Jianghong Meng4, Xiayidan Wufuer5, Mingliu Wang6, Meilian Huang7, Jianhui Chen8, Chunmei Jing9, Zhiying Xiong1, Mei Zeng10, Ming Liao1, Jianmin Zhang1.
Abstract
PURPOSE: Human infections caused by invasive non-typhoidal Salmonella (iNTS) are highly prevalent worldwide. However, data for such infections in China are scarce. This study reports the epidemiology of iNTS in China.Entities:
Keywords: China; beta-lactamases; fluoroquinolones; invasive non-typhoidal Salmonella; multidrug resistant; pulsed field gel electrophoresis
Year: 2019 PMID: 31571942 PMCID: PMC6750164 DOI: 10.2147/IDR.S210961
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Antimicrobial susceptibility among 178 invasive non-typhoidal Salmonella isolates from humans in China, during 2007 to 2016
| No. of strains resistant to indicated agent at the indicated breakpoint in mg/L (% resistance)a | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of strains | MDR phenotype | CIP | CTX | CFP ≥32 | PB ≥8 | OFX ≥2 | AMP ≥32 | SUL ≥512 | C ≥32 | TET ≥16 | NA ≥32 | STR ≥64 | |||
| ≥1 | >0.06and <1 | ≥4 | 0.25–2 | ||||||||||||
| Enteritidis | 57 | 24 (42.1) | 2 (3.5) | 8 (14) | 3 (5.3) | 10 (17.5) | 0 | 0 | 2 (3.5) | 5 (8.8) | 32 (56.1) | 0 | 6 (10.5) | 47 (82.5) | 32 (56.1) |
| Choleraesuis | 47 | 38 (80.9) | 15 (31.9) | 17 (36.2) | 2 (4.3) | 14 (29.8) | 1 (2.1) | 2 (4.3) | 16 (34) | 2 (4.3) | 35 (74.5) | 32 (68.1) | 30 (63.8) | 42 (89.4) | 29 (61.7) |
| Typhimurium | 24 | 17 (70.8) | 4 (16.7) | 6 (25) | 2 (8.3) | 4 (16.7) | 1 (4.2) | 0 | 5 (20.8) | 3 (12.5) | 13 (54.2) | 8 (33.3) | 18 (75) | 13 (54.2) | 12 (50) |
| Derby | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (25) | 1 (25) | 0 | 0 |
| London | 5 | 2 (40) | 0 | 3 (60) | 0 | 0 | 0 | 0 | 0 | 0 | 3 (60) | 2 (40) | 3 (60) | 0 | 0 |
| Give | 4 | 1 (25) | 0 | 2 (50) | 0 | 0 | 0 | 0 | 0 | 0 | 2 (50) | 1 (25) | 1 (25) | 3 (75) | 1 (25) |
| Livingstone | 4 | 3 (75) | 0 | 3 (75) | 2 (50) | 2 (50) | 0 | 0 | 0 | 2 (50) | 3 (75) | 4 (100) | 4 (100) | 0 | 2 (50) |
| Virehow | 4 | 2 (50) | 2 (50) | 0 | 0 | 0 | 0 | 0 | 2 (50) | 0 | 2 (50) | 0 | 2 (50) | 2 (50) | 0 |
| Weltevreden | 3 | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 2 (66.7) | 0 | 0 | 0 | 0 |
| Indiana | 2 | 2 (100) | 2 (100) | 0 | 2 (100) | 0 | 0 | 0 | 2 (100) | 2 (100) | 2 (100) | 0 | 0 | 2 (100) | 0 |
| Meleagridis | 2 | 2 (100) | 0 | 1 (50) | 2 (100) | 0 | 1 (50) | 0 | 0 | 2 (100) | 2 (100) | 1 (50) | 1 (50) | 2 (100) | 1 (50) |
| Thompson | 2 | 2 (100) | 2 (100) | 0 | 2 (100) | 0 | 0 | 0 | 0 | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) |
| Others | 20 | 2 (10) | 0 | 1 (5) | 0 | 1 (5) | 0 | 0 | 0 | 0 | 7 (35) | 1 (5) | 3 (15) | 1 (5) | 2 (10) |
| Total | 178 | 95 (53.4) | 27 (15.2) | 42 (23.6) | 15 (8.4) | 31 (17.4) | 3 (1.7) | 2 (1.1) | 27 (15.2) | 18 (10.1) | 105 (59) | 52 (29.2) | 71 (39.9) | 114 (64) | 81 (45.5) |
Notes: aAll isolates were susceptible to Imipenem. The resistance breakpoint for ciprofloxacin is ≥1 mg/L and for cefotaxime is ≥4 mg/L.
Abbreviations: CIP, ciprofloxacin; CTX, cefotaxime; CFP, cefepime; PB, polymyxin B; OFX, ofloxacin; AMP, ampicillin; SUL, Sulfisoxazole; C, chloramphenicol; TET, tetracycline; NA, nalidixic acid; STR, streptomycin; MDR, multidrug resistant.
Figure 1Prevalence of invasive non-typhoidal Salmonella in the People’s Republic of China by rainfall.
Trends in resistance to quinolones, cefotaxime, cefepime, MDR and ACSSuT pattern among iNTS isolates during the study period
| Period of isolation | No.(%) susceptiblea | No. (%) MDRb | No. (%) CIPR | No. (%) NAR | No. (%) CTXR | No. (%) CFPR | No. (%) ACSSuT | Year isolation no. |
|---|---|---|---|---|---|---|---|---|
| 2007 | 0 | 8 (80) | 0 | 4 (40) | 0 | 0 | 0 | 10 |
| 2008 | 1 (16.7) | 4 (66.7) | 0 | 2 (33.3) | 0 | 0 | 0 | 6 |
| 2009 | 2 (20) | 7 (70) | 0 | 5 (50) | 0 | 0 | 0 | 10 |
| 2010 | 2 (13.3) | 11 (73.3) | 2 (13.3) | 8 (53.3) | 0 | 0 | 0 | 15 |
| 2011 | 2 (10) | 13 (65) | 4 (20) | 14 (70) | 0 | 0 | 0 | 20 |
| 2012 | 2 (14.3) | 8 (57.1) | 2 (14.3) | 9 (64.3) | 2 (14.3) | 0 | 0 | 14 |
| 2013 | 2 (8.3) | 13 (54.2) | 4 (16.7) | 16 (66.7) | 3 (12.5) | 0 | 0 | 24 |
| 2014 | 4 (18.2) | 11 (50) | 4 (18.2) | 15 (68.2) | 3 (13.6) | 0 | 2 (9.1) | 22 |
| 2015 | 2 (9.5) | 9 (42.9) | 4 (19) | 14 (66.7) | 2 (9.5) | 1 (4.8) | 1 (4.8) | 21 |
| 2016 | 4 (11.1) | 11 (30.6) | 7 (19.4) | 27 (75) | 5 (13.9) | 2 (5.6) | 4 (11.1) | 36 |
| Total | 21 (11.9) | 95 (53.4) | 27 (15.2) | 114 (64) | 15 (8.4) | 3 (1.7) | 7 (3.9) | 178 |
Abbreviations: susceptiblea, susceptible to all tested antibiotics; MDRb, resistance to three or more antimicrobial classes; CIPR, ciprofloxacin resistant; NAR, nalidixic acid resistant; CTXR, cefotaxime resistant; CFPR, cefepime resistant; ACSSuT, resistance to tetracycline, sulfamethoxazole, streptomycin, chloramphenicol and ampicillin.
Figure 2The trend of resistance to invasive non-typhoidal Salmonella (iNTS) isolates annually from 2007 to 2016. Numbers in brackets indicate the total number of iNTS isolates cultured in each year in China. Proportions that were nalidixic acid resistant (NAR) and multidrug resistant (MDR). Also shown are cefotaxime- (CTX) and ACSSuT resistant patterns among the iNTS isolates.
The resistance phenotype and bla genes of 15 cefotaxime-resistant isolates and 1 isolate with ACSSuT pattern without resistant to cefotaxime
| No. | Source | Age | Date | Serovar | CTXa | CFPa | CIPa | Other resistance phenotype | Bla genes | PMQR genes |
|---|---|---|---|---|---|---|---|---|---|---|
| P1 | Blood/SH | 21d | 12/1/6 | Indiana | 16 | 2 | 8 | OFX,SUL,NA | TEM-1, CTX-M-55, OXA-1 | qnrA, qnrB, Aac (6´)-Ib-cr |
| P2 | Blood/SH | 19y | 12/6/25 | Enteritidis | 32 | 2 | 0.06 | AMP, SUL,N A | TEM-1, OXA-1 | - |
| P3 | CSF/SH | 11m | 13/1/11 | Indiana | 16 | 2 | 8 | AMP, OFX, SUL, NA | TEM-1, CTX-M-55, OXA-1 | qnrS, Aac (6´)-Ib-cr |
| P4 | Blood/SH | 1y | 13/10/13 | Meleagridis | 4 | 0.5 | 0.06 | AMP, SUL, STR, NA | TEM-1, CTX-M-55, SHV-2 | - |
| P5 | Blood/GX | 52y | 13/4/5 | Choleraesuis | 128 | 2 | 1 | AMP,C,TET,STR,NA | TEM-1, CTX-M-55, OXA-1 | qnrB, qnrS, Aac (6´)-Ib-cr |
| P6 | Blood/FJ | 1y | 14/12/1 | Thompson | 8 | 0.125 | 4 | ACSSuT, NA | TEM-1, CMY-2 | - |
| P7 | Aspirates/CQ | 11m | 14/2/20 | Thompson | 8 | 0.125 | 2 | ACSSuT, NA | TEM-1 | - |
| P8 | Blood/GX | 64y | 14/11/8 | Typhimurium | 128 | 0.25 | 1 | AMP,C,TET, NA | TEM-1, CMY-2 | - |
| P9 | Blood/SH | 83y | 15/6/18 | Enteritidis | 128 | 4 | 0.5 | AMP, NA | TEM-1 | qnrD |
| P10 | Aspirates/GX | 36y | 15/11/18 | Meleagridis | 512 | 32 | 0.5 | AMP,SUL,C,TET,NA | TEM-1, CMY-2 | - |
| P11 | Blood/CQ | 3m | 16/6/10 | Enteritidis | 256 | 16 | 0.25 | AMP | TEM-1 | - |
| P12 | Blood/SH | 4m | 16/7/28 | Livingstone | 64 | 0.5 | 0.25 | ACSSuT | TEM-1, CMY-2 | - |
| P13 | Blood/SH | 51y | 16/7/5 | Livingstone | 64 | 0.5 | 0.25 | ACSSuT | TEM-1, CMY-2 | - |
| P14 | Blood/GX | 52y | 16/9/5 | Choleraesuis | 128 | 32 | 1 | ACSSuT, PB, NA | CTX- M-55, OXA-1 | Aac (6´)-Ib-cr |
| P15 | Blood/SH | 59y | 16/6/2 | Typhimurium | 256 | 32 | 0.5 | ACSSuT, NA | TEM-1,CTX-M-55 | qnrS |
| P16 | Aspirates/CQ | 9m | 15/9/15 | Typhimurium | 0.5 | 0.25 | 2 | ACSSuT, NA | None | None |
Notes: aIndicates units of related antibiotics is mg/L. Gray shading indicates the isolate with ACSSuT pattern without resistant to cefotaxime. None indicates that the relevant genes were not tested. - indicates that the relevant genes were tested but not detected.
Abbreviation: CSF, cerebrospinal fluid; d, day; m, month; y, year; SH, Shanghai; GX, Guangxi; CQ, Chongqing; FJ, Fujian.
Relationship between ciprofloxacin MIC, point mutations within the QRDRs of DNA gyrase and topoisomerase IV subunit genes and PMQR genes in 114 NAR iNTS isolates
| CIP MIC (mg/L) | No. of isolates | Amino acid change in GyrA | Amino acid change in ParC | Amino acid change in ParE | No. (%) Multiple mutations ratea | No. (%) Mutation rateb | No. (%) PMQR genes ratec |
|---|---|---|---|---|---|---|---|
| 0-0.125 | 47 | Asp87→Tyr [26], Asp87→Asn [12], Asp87→Gly [5], Ser83→Tyr [4] | 47 (100) | 25 (53.2) | |||
| 0.25–0.5 | 40 | Ser83→Tyr[15], Asp87→Gly [8], Asp87→Asn [6], Asp87→Tyr [5], Ser83→Phe [1] | Thr57→Ser [24], Ser80→Arg [8], Gly78→Cys [1] | 23 (57.5) | 40 (100) | 29 (72.5) | |
| 1–2 | 21 | Ser83→Tyr [14], Asp87→Gly [2], Asp87→Tyr [2], Asp87→Asn [1] | Thr57→Ser [19], Gly78→Cys [6], Ser80→Arg [1] | 19 (90.5) | 19 (90.5) | 10 (47.6) | |
| ≥4 | 6 | Ser83→Tyr [3], Ser83→Phe [3], Asp87→Asn [3], Asp87→Gly [3] | Thr57→Ser [6], Ser80→Arg [3], Ser80→Ile [3] | Asp530→Asn [2], Ala538→Thr [3], Ser458→Pro [1] | 6 (100) | 6 (100) | 3 (50) |
Notes: Alterations in the QRDRs of gyrB were not found in any of the isolates tested. The a indicates that isolates exhibit at least two mutations in the QRDRs. The b indicates that isolates exhibit one mutation in the QRDRs. The c indicates that isolates exhibit both mutations in the QRDRs and PMQR gene.
Abbreviations: CIP, ciprofloxacin; MIC, minimum inhibitory concentration.
Figure 3Dendrogram of pulsed field gel electrophoresis (PFGE) patterns of 57 Salmonella Enteritidis isolates recovered from these five provinces. Six clusters (A–F) were identified.
Figure 4Dendrogram of pulsed field gel electrophoresis (PFGE) patterns of 24 Salmonella Typhimurium isolates recovered from these five provinces. Nine clusters (A–I) were identified.